Investing Made Simple
Market Musings 1/26/2022 Quick thoughts on the markets and major portfolio news. Not on Ursa yet? Download Ursa from the App Store! Fed commentary alluded to increasingly aggressive stance, but didn’t provide much concrete details. We continue to believe Fed will need to get more aggressive through 2022 to combat #InflationFears. #RisingYields fear has fueled Read More
🥱 Dec inflation hits 7%. Dec 12-month CPI hit 7% up from Nov’s 6.8% reading. Viewing #InflationFears potentially moderating, investors initially cheered results Wed though optimism lost stream by end of day. 🧐 Stagnant market. Markets struggling for direction as investors remain focused on #RisingYields. Some analysts now predicting 4 rate hikes this year while Fed trying to soothe markets Read More
🧪 No US lockdown. Biden announced 🇺🇸 #COVID19 Omicron plan focusing on vaccination and testing vs. lockdowns. Fearing a shutdown similar to many in Europe, announcement kicked off week-long rally on Omicron optimism. 🥳 Lots of Omicron cheer. Looking past surging cases, investors rally into the holidays on #COVID19 Omicron optimism. It seems like Omicron surges to a peak quickly with milder Read More
🦅 Fed shifting to offense. Fed turns hawkish to combat surging #InflationFears. Fed accelerating tapering plan doubling monthly reduction to $30B and targeting 3 rate hikes in 2022 (up from just one expected last month). We think even the accelerated expectations may still be conservative… 😷 Omicron surging globally. While still milder symptoms generally, high transmissibility has #COVID19 Omicron surging Read More
😬 Omicron anxiety. Big market movements all week with small bits of #COVID19 Omicron news trickling out. Investors remain super anxious with #COVIDRecovery uncertainty from new variant. S&P 500 ends down -1% for week. 💸 Transient no more? Powell is retiring describing inflation as ‘transient’ and considering accelerating asset tapering timeline. Quick tone change from just a couple weeks ago signaling #InflationFears risk Read More
Market Musings 12/2/2021 Quick thoughts on the markets and major portfolio news. Not on Ursa yet? Download Ursa from the App Store! Market rollercoaster since Omicron news broke Black Friday. We’re closely monitoring severity of symptoms, transmissibility and potential vaccine immunity for signal on #COVIDRecovery. It was a different Black Friday than we were expecting. Read More
🦠 Omicron variant fears. New #COVID19 variant Omicron surging in South Africa has countries globally restricting travel again. Still a lot unknown about the new variant, but rampant speculation and thinly traded Black Friday sent markets nose-diving. S&P 500 fell over -2%. #COVIDRecovery names hit hard, but #RevengeTravel including hotels and airlines decimated. 🏦 Powell renominated. Overshadowed by Omicron, Biden renominated Fed Chair Read More
🛍 Strong retail spending. Retail #earnings were strong highlighting #COVIDRecovery consumer demand remains intact despite #InflationFears. However, #SupplyScare issues remain heading into Q4. Consumer up +4% for week. 🦠 4th Wave? #COVID19 resurgence in Europe as rising case has Austria mandating 20-day lockdown and Germany not ruling out potential lockdown either. Even cases troughed weeks ago and rising again. Volatile market as #COVIDRecovery keeps starting and stopping. ️💸 Read More
Market Musings 11/3/2021 Quick thoughts on the markets and major portfolio news. Not on Ursa yet? Download Ursa from the App Store! We expect supply chain improvement starting early next year, but unfortunately, #SupplyScare is likely peaking in the all-important Q4 holiday season. It was a recurring theme this #earnings season. Company after company reported Read More
🚢 Supply shortages. #SupplyScare has companies scrambling to build and ship products. Component shortages, labor shortages, rising fuel costs and delayed logistics all compounding the issue. Not boding well for Q4 🎄 season. ⚾️ Revenue strikes out. Revenue missing Street expectations is a recurring theme this #earnings season. #COVIDRecovery demand seems to be there, but companies can’t produce enough product due to #SupplyScare issues. 💸 Yields Read More